← feed

Is NCT03448497 results overdue?

Yes — results are overdue. Primary completion was 2018-04-27; the FDAAA-801 reporting deadline (2019-04-27) passed 2658 days ago and no results are posted on ClinicalTrials.gov.

Study of First-line Treatment Patterns and Clinical Outcomes in Patients With Advanced Melanoma in the United Kingdom

NCT IDNCT03448497 ↗
SponsorBristol-Myers Squibb (INDUSTRY)
Public issuerBRISTOL MYERS SQUIBB CO — BMY (CIK 0000014272) best-effort name match, 95% conf — verify on EDGAR ↗
Phase
StatusCOMPLETED
Primary completion2018-04-27 (ACTUAL)
Reporting deadline2019-04-27 (completion + 365d)
Days overdue2658
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-06-21 · SHA-256 e3f2fa43a5da8506… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT03448497. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →